Airway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis

Benedikt Jaeger(Fraunhofer Institute for Toxicology and Experimental Medicine), Jonas C. Schupp(Yale University), Linda Plappert(Fraunhofer Institute for Toxicology and Experimental Medicine), Oliver Terwolbeck(Fraunhofer Institute for Toxicology and Experimental Medicine), Nataliia Artysh(Medizinische Hochschule Hannover), Gian Kayser(University Medical Center Freiburg), Peggy Engelhard(University Medical Center Freiburg), Taylor Adams(Yale University), Robert Zweigerdt(Medizinische Hochschule Hannover), Henning Kempf(Medizinische Hochschule Hannover), Stefan Lienenklaus(Medizinische Hochschule Hannover), Wiebke Garrels(Medizinische Hochschule Hannover), Irina Nazarenko(University of Freiburg), Danny Jonigk(Medizinische Hochschule Hannover), Małgorzata Wygrecka(Justus-Liebig-Universität Gießen), Denise Klatt(Medizinische Hochschule Hannover), Axel Schambach(Boston Children's Hospital), Naftali Kaminski(Yale University), Antje Prasse(Medizinische Hochschule Hannover)
Nature Communications
September 26, 2022
Cited by 144Open Access
Full Text

Abstract

Abstract Idiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options. In this study, we focus on the properties of airway basal cells (ABC) obtained from patients with IPF (IPF-ABC). Single cell RNA sequencing (scRNAseq) of bronchial brushes revealed extensive reprogramming of IPF-ABC towards a KRT17 high PTEN low dedifferentiated cell type. In the 3D organoid model, compared to ABC obtained from healthy volunteers, IPF-ABC give rise to more bronchospheres, de novo bronchial structures resembling lung developmental processes, induce fibroblast proliferation and extracellular matrix deposition in co-culture. Intratracheal application of IPF-ABC into minimally injured lungs of Rag2 −/− or NRG mice causes severe fibrosis, remodeling of the alveolar compartment, and formation of honeycomb cyst-like structures. Connectivity MAP analysis of scRNAseq of bronchial brushings suggested that gene expression changes in IPF-ABC can be reversed by SRC inhibition. After demonstrating enhanced SRC expression and activity in these cells, and in IPF lungs, we tested the effects of saracatinib, a potent SRC inhibitor previously studied in humans. We demonstrate that saracatinib modified in-vitro and in-vivo the profibrotic changes observed in our 3D culture system and novel mouse xenograft model.


Related Papers

No related papers found

Powered by citation graph analysis